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Jefferson’s Heart Transplant Program 
reactivated this year with a new, 
system-wide approach to heart 
failure that makes innovative, 
evidence-based, comprehensive  
care more accessible to patients 
throughout the Delaware Valley.  
The program is led by surgeon  
H. Todd Massey, MD, as Surgical 
Director of Cardiac Transplantation 
and Mechanical Circulatory Support 
and cardiologist Andrew Boyle, MD, 
as Medical Director of Advanced 
Heart Failure. 
“By implementing consistent 
standards at all Jefferson Health 
locations, patients with end-stage 
heart failure can receive the same 
care whether they come to Center 
City, see physicians at Abington or 
Aria or interact with us through our 
JeffConnect telehealth platform,”  
Dr. Massey explains. “Our approach 
helps ensure that patients with early-
stage heart failure are taking the right 
medications while giving all patients 
access to the latest clinical trials.”
Joining Dr. Massey in Center City are 
Drs. John Entwistle, Louis Samuels, 
and Vakhtang Tchantchaleishvili, 
Physician Assistant Joshua Park, and 
Nurse Practitioners Dannett Durphy 
and Chuck Rowland. The Director of 
the Division of Cardiothoracic Surgery, 
Rohinton Morris, MD, sees patients  
in both Center City and Abington.  
Dr. Massey says it’s a team whose 
experience is unparalleled.
“Our surgeons have extensive 
experience in transplant, mechanical 
circulatory support and artificial 
heart,” Dr. Massey notes. “Few, if any, 
programs can match the patient 
volume that we collectively have  
been involved in over the course  
of our careers.”
Jefferson’s Heart Transplant Program 
offers all of the latest technologies, 
including the HeartMate 3™ Left 
Ventricular Assist System as well as 
SynCardia, the only FDA approved 
temporary total artificial heart system. 
As Dr. Massey explains, helping 
develop and evaluate further 
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At Thomas Jefferson University Hospital in Center City, H. Todd Massey, MD (right), leads the Cardiac 
Transplantation and Mechanical Circulatory Support component of the Heart Transplant Program. Pictured are 
Vakhtang Tchantchaleishvili, MD; Joshua Park, PA-C; Chuck Rowland, MSN, CRNP; John Entwistle, MD, PhD,  
and Louis Samuels, MD.
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At the Heart of Innovation:  
Jefferson’s Heart Transplant Program 
Like every surgeon, I started my  
residency training in General Surgery. 
Then I specialized in Thoracic and 
Cardiovascular Surgery and finally 
sub-specialized with a Fellowship in  
Heart and Lung Transplantation and  
Adult Cardiac Surgery at Duke University 
Medical Center. At the time I went 
through training, we didn’t have a lot  
of good options to help patients with 
advanced heart failure. I was working with 
very sick patients, many of whom died. 
Back then, many of my colleagues 
questioned why I would choose this as  
my focus. They were right that the 
treatments weren’t great at the time.  
But over the past 25 years or so, I have 
not only witnessed but also been part  
of incredible innovations. 
Today, we have some excellent solutions 
and we’ve made a huge impact. It’s 
incredible both to look back at our 
progress and to look ahead and imagine 
how much more we can achieve.
H. Todd Massey, MD 
Surgical Director, Cardiac Transplantation 
and Mechanical Circulatory Support 
Professor, Cardiothoracic Surgery
refinements and innovations remains 
a priority. He cites the example of Left 
Ventricular Assist Devices (LVADs), 
which early on had some issues in 
terms of durability and adverse events. 
“Since then, we have been able to 
support much better, and generate 
much more enduring outcomes for 
patients,” he notes. “As the technology 
continues to evolve, we are excited 
about opportunities to improve 
energy delivery to these systems, 
which must perform 24/7/365.”
Another area primed for innovation: 
preservation and transport of donor 
hearts. Since the 1960s, static 
preservation has been the approach 
– with clinicians using chemical 
solutions to put hearts to “sleep” 
before placing them on ice in coolers 
for transport. 
“Today, there are systems being 
developed and tested that either 
perfuse a donor heart with warm 
blood during transport or that 
replenish the heart with crystalloid-
based solutions,” he says. “These hold 
the promise of two important 
advantages: being able to extend the 
time and distance that a donor heart 
can travel and making it possible to 
resuscitate a heart that historically 
would have proven unusable.” 
As innovations continue to take shape, 
Jefferson Health will be at the 
forefront of treating heart failure with 
proven, system-wide protocols – 
whether managing early-stage heart 
failure with medication or addressing 
later-stage disease by implanting 
increasingly sophisticated devices or 
performing cardiac transplants. 
“We are truly combining international 
expertise with local care and 
convenience,” Dr. Massey says. 
For more information, go to 
JeffersonHealth.org/Heart
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